heparin-induced thrombocytopenia

(redirected from Heparin-induced thrombocytopenia and thrombosis)

heparin-induced thrombocytopenia

Acquired thrombocytopenia affecting some heparin-treated Pts–HTPs, defined as a ↓ platelet count during or shortly after heparin exposure; HIT is a markedly prothrombotic disorder seen in Pts who are at a high baseline risk for venous thrombosis DiffDx Antiphospholipid antibody syndrome, DIC, Trousseau syndrome–migratory thrombophlebitis & malignancy, TTP/HUS, thrombocytopenia and 'showers' of microthrombi Clinical HIT occurs 6-10 days after heparin exposure Diagnosis Aggregation studies using platelets from Pts known to be sensitive to antibody; quantification of serotonin release from platelets radiolabeled with serotonin in assay using Pt serum.

heparin-induced thrombocytopenia

Thrombocytopenia caused by an immune reaction to heparin. It may lead to widespread or potentially life-threatening blood clotting rather than bleeding. See: white-clot syndrome

CAUTION!

Patients whose platelet counts drop significantly during exposure to heparin should discontinue the drug immediately.

heparin-induced thrombocytopenia

A blood platelet deficiency disorder caused by a reaction to heparin. The condition is caused by antibodies, usually of the IgG class against a heparin-platelet factor IV complex on the surface of platelets. Paradoxically, the condition features thrombosis and embolism with the risk of stroke and other serious arterial occlusion effects. This is because the immune complexes formed combine with the antibody Fc receptors of platelets causing their activation and the initiation of clotting.
References in periodicals archive ?
Heparin Sodium is contraindicated in patients with history of Heparin-Induced Thrombocytopenia and Heparin-Induced Thrombocytopenia and Thrombosis, known hypersensitivity to heparin or pork products, those whom suitable blood coagulation tests cannot be performed at appropriate intervals and patients with uncontrolled bleeding states, except when this is due to disseminated intravascular coagulation.
This 505(b)(2) NDA for RTU bivalirudin product is now under the US FDA's review for its approval for the treatment of patients undergoing percutaneous coronary intervention (PCI) with use of glycoprotein IIb/IIIa inhibitor as well as undergoing PCI with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome, or (3) with unstable angina undergoing percutaneous transluminal coronary angioplasty (PTCA).
Boshkov LK, Warkentin TE, Hayward CP, Andrew M, Kelton JG 1993 Heparin-induced thrombocytopenia and thrombosis: clinical and laboratory studies British Journal of Haematology 84 (2) 322-328
Heparin-induced thrombocytopenia and thrombosis. N Engl J Med 1995;332(2):1374-6.
ANGIOMAX is being examined in patients undergoing angioplasty with heparin-induced thrombocytopenia and heparin-induced thrombocytopenia and thrombosis. The company is also developing a second product, CTV-05, a proprietary biotherapeutic agent with a potentially broad range of applications in the treatment of gynecological and reproductive infections.
Fc[Gamma]RIIa His/Arg 131 polymorphism subclass-specific IgG anti-heparin/PF4 antibodies and clinical course in patients with heparin-induced thrombocytopenia and thrombosis. Blood.
The product is indicated in patients undergoing percutaneous coronary intervention with provisional use of GPI and in patients at risk of heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing percutaneous coronary intervention.
ANGIOMAX is indicated in patients undergoing percutaneous coronary intervention (PCI) with provisional use of GPI and in patients with, or at risk of, heparin-induced thrombocytopenia and thrombosis syndrome (HIT/HITTS) undergoing PCI.

Full browser ?